$7.7 MILLION AWARDED IN NEW FEDERAL FUNDING FOR CANCERS IN CHILDREN AND AYAS, BRINGING THREE-YEAR TOTAL TO $17 MILLION
Over the past three years, Rally’s national advocacy efforts have resulted in $17 million in new federal funding for cancers in children, adolescents and young adults within the Peer Reviewed Cancer Research Program (PRCRP) via the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP).
Cancers in children, adolescents and young adults received $7.7 million for 10 awards in 2019, $6.5 million for 11 awards in 2018 and $3.3 million for seven awards in 2017.
APPLY FOR 2020 DoD CDMRP GRANTS
$110 MILLION WITHIN THE PRCRP AVAILABLE FOR PEDIATRIC, ADOLESCENT AND YOUNG ADULT CANCERS
Application Deadlines
- May 14, 2020: Idea Award and Impact Award Pre-Proposal Due
- July 30, 2020: Career Development Award, Virtual Cancer Center Award, Translational Team Science Award, and Behavioral Health Science Award Letter of Intent Due
- August 27, 2020: Full Applications for All Above Awards Due
For more information, visit cdmrp.army.mil/funding/prcrp
Want to receive emails regarding DoD CDMRP funding opportunities?
HELPFUL SUBMISSION TIPS & INSIGHTS
In this Rally-hosted webinar, PRCRP Program Manager Dr. Donna Kimbark, Ph.D. provides expert insights and best practices for completing and submitting your DoD funding application.
2018 PRCRP Awards for Cancers in Children, Adolescents and Young Adults
In 2018 Cancers in Children, Adolescents and Young Adults was just one of the 17 topic areas under the Peer Reviewed Cancer Research Program (PRCRP). With $80 million available, Cancers in Children, Adolescents and Young Adults secured $6.5 million in awards. The table below highlights the 2018 awards so that you may gain a sense of the award mechanisms available. Since that time, available funding under the PRCRP has increased to $110 million across 14 topic areas. To see the 2019 awards that have been recommended for funding under all PRCRP topic areas visit: https://cdmrp.army.mil/prcrp/awards/awards.
| PI | Hospital | Title | Type | Amount |
| Natalie Boehnke | Massachusetts Institute of Technology | Leveraging Rational Nanoparticle Design for Improved Treatment of Pediatric and Adolescent Cancers (Sarcomas and Blasomas) | Horizon Award | $155,000 |
| Rikhia Chaudhury Chakraborty | Baylor College of Medicine | Therapeutic Targeting of Immune Dysfunction in Langerhans Cell Histiocytosis | Career Development Award | $577,246 |
| Carri Geer | Novan, Inc. | Topical Nitric Oxide Therapy to Treat Cervical Neoplasias and Prevent HPV-Associated Cancers | Impact Award | $1,215,182 |
| Andrew Hong | Dana-Farber Cancer Institute | Functional Interrogation of Nuclear Export Inhibition in SMARCB1-Deficient Cancers (Sarcomas) | Career Development Award | $633,993 |
| Liesl Lawrence | University of Texas Health Science Center at San Antonio | Transcription, R-Loops, and RNA Splicing in Ewing Sarcoma | Horizon Award | $220,350 |
| Miguel Miranda-Roman | Memorial Sloan Kettering Cancer Center | Overcoming Resistance to MEK Inhibitor Treatment in Malignant Peripheral Nerve Sheath Tumor (MPNST) | Horizon Award | $264,375 |
| Caitlin Murphy | University of Texas Southwestern Medical Center at Dallas | Fertility and Reproductive Outcomes of Adolescent and Young Adult Cancer Survivors in Texas | Career Development Award | $580,648 |
| Christopher Porter | Emory University | Development of Bispecific, T-Cell Engaging, Cytokine-Loaded Nanoparticles (BiTEokines) for the Treatment of Childhood Cancers (Leukemias) | Idea Award with Special Focus | $624,000 |
| Mark Purdue | National Cancer Institute | An Investigation of Serum Levels of Per- and Polyfluoroalkyl Substances and Testicular Cancer Risk Within the Department of Defense Serum Repository | Idea Award with Special Focus | $452,604 |
| Bo Kyung A Seong | Dana-Farber Cancer Institute | Targeting Pediatric Fusion Oncoproteins via Protein Degradation (Osteosarcoma and Neroblastoma) | Horizon Award | $264,750 |
| Raymond Yeung/Venu Pillarisetty/Taran Gujral | University of Washington/Fred Hutchinson Cancer Research Center | Novel Therapeutics for Fibrolamellar Carcinoma (Children and AYA) | Translational Team Science Award | $1,539,441 |